Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Research & Development (2016 - 2025)

Historic Research & Development for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $28.2 million.

  • Myriad Genetics' Research & Development fell 105.26% to $28.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.5 million, marking a year-over-year increase of 1182.27%. This contributed to the annual value of $113.4 million for FY2024, which is 2784.67% up from last year.
  • As of Q3 2025, Myriad Genetics' Research & Development stood at $28.2 million, which was down 105.26% from $25.6 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Research & Development ranged from a high of $32.2 million in Q4 2024 and a low of $18.8 million during Q3 2021
  • For the 5-year period, Myriad Genetics' Research & Development averaged around $23.7 million, with its median value being $23.1 million (2021).
  • Its Research & Development has fluctuated over the past 5 years, first tumbled by 4273.74% in 2021, then surged by 5333.33% in 2024.
  • Myriad Genetics' Research & Development (Quarter) stood at $20.5 million in 2021, then rose by 14.15% to $23.4 million in 2022, then dropped by 10.26% to $21.0 million in 2023, then surged by 53.33% to $32.2 million in 2024, then fell by 12.42% to $28.2 million in 2025.
  • Its last three reported values are $28.2 million in Q3 2025, $25.6 million for Q2 2025, and $27.5 million during Q1 2025.